Century Therapeutics, Inc. (IPSC) Stock Price & Analysis

Century Therapeutics, Inc. (IPSC) rose 0.96% to USD 2.11 as of September 8, 2026 at 05:47 UTC, according to Nexqual real-time market data.

IPSC last closed at USD 2.11; the session ranged USD 2.06–2.15 on volume of 300,380 shares. Market capitalization is —, with a 52-week range of USD 0.44–3.04 (NCM). Source: Nexqual, September 8, 2026 at 05:47 UTC.

Key Statistics (as of September 8, 2026 at 05:47 UTC)

Technical Analysis (IPSC)

Nexqual's technical model rates IPSC "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:47 UTC.

From Century Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We have sought patent protection in the United States and other countries throughout the world related to each of our pipeline programs, including our CNTY-101 product candidate, as well as other iPSC-derived engineered CAR-expressing and beta-islet cells comprising certain transgene insertions and deletions, including our proprietary Allo-Evasion™ technology.
• Incorporating industry-leading iPSC differentiation know-how, CRISPR-mediated precision gene editing, sophisticated protein engineering, proprietary Allo-Evasion™ technology, and cutting-edge manufacturing, we seek to provide patients with improved treatment options.
• Our first investigational solid tumor CAR-T cell program is designed to target validated tumor antigens including Nectin-4 (present on several solid tumors including urothelial cancer, breast cancer and lung cancer) and others using our own proprietary developed CAR moieties.
• This portfolio covers compositions of programmed cellular immunotherapies, our proprietary Allo-Evasion™ technology and our platform for industrial scale iPSC engineering and differentiation.

Partnerships

• On September 22, 2023, we entered into a worldwide license agreement with FCDI, or the Autoimmune License, whereby FCDI will grant non-exclusive licenses to us for certain patent rights and know-how related to cell differentiation and reprogramming for the development and commercialization of iPSC-derived therapies for the treatment of inflammatory and autoimmune diseases.
• Inscripta In January 2019, we entered into a non-exclusive license agreement with Inscripta, Inc.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:47 UTC. This page is informational and not investment advice.